Seki Yoshitaka, Okusaka Takuji, Ikeda Masafumi, Morizane Chigusa, Ueno Hideki
Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
Jpn J Clin Oncol. 2009 Nov;39(11):751-5. doi: 10.1093/jjco/hyp085. Epub 2009 Aug 8.
Pancreatic acinar cell carcinoma (ACC) is a comparatively rare tumor and account for approximately 1% of all cases of pancreatic cancer. Clinical presentation is usually related to either local spread or metastasis. The clinical features, especially those related to the prognosis and treatment outcomes, have not yet been fully clarified. There are no established treatments for unresectable pancreatic ACC. We administered gemcitabine monotherapy to four patients with ACC; however, the results were not satisfactory. Disease control without obvious tumor shrinkage was observed in one patient. Another patient showed severe renal damage caused by gemcitabine. On the other hand, fluoropyrimidine-based chemotherapy may have some activity against this tumor, because one of the three patients who received S-1 as second-line chemotherapy showed a partial response. Prospective clinical trials are necessary to confirm the effectiveness of fluoropyrimidine for the treatment of pancreatic ACC.
胰腺腺泡细胞癌（ACC）是一种相对罕见的肿瘤，约占所有胰腺癌病例的1%。临床表现通常与局部扩散或转移有关。其临床特征，尤其是与预后和治疗结果相关的特征，尚未完全阐明。对于无法切除的胰腺ACC，尚无既定的治疗方法。我们对4例ACC患者进行了吉西他滨单药治疗；然而，结果并不令人满意。1例患者出现了无明显肿瘤缩小的疾病控制。另1例患者出现了吉西他滨引起的严重肾损伤。另一方面，基于氟嘧啶的化疗可能对这种肿瘤有一定活性，因为接受S-1作为二线化疗的3例患者中有1例出现了部分缓解。需要进行前瞻性临床试验来证实氟嘧啶治疗胰腺ACC的有效性。
